Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.61 USD | -1.86% | +1.22% | +34.06% |
Apr. 19 | Lake Street Starts Cellebrite DI With Buy Rating, $13 Price Target | MT |
Apr. 01 | BofA Securities Adjusts Cellebrite DI Price Target to $13 From $12, Maintains Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 72.9 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+34.06% | 2.38B | - | ||
+11.31% | 87.43B | B | ||
+7.52% | 79.69B | B+ | ||
-11.90% | 56.79B | B+ | ||
+23.30% | 47.14B | D+ | ||
+32.46% | 46.62B | D+ | ||
-26.51% | 45.5B | B- | ||
+81.90% | 42.31B | D+ | ||
-6.42% | 25.81B | C+ | ||
+21.21% | 22.27B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLBT Stock
- Ratings Cellebrite DI Ltd.